Supportive Oligonucleotide Therapy (SOT) for Lyme & Others

As Seen On...

Anti-Sense Oligonucleotide Therapy (AOT) for Lyme, Lyme co-infections and other viruses

RGCC Laboratory, located in Greece, is a genetic laboratory capable of identifying the specific gene sequences of different targets such as cancer, Lyme and other viruses. 

SOT is a treatment that was originally created in Europe over 20 years ago by the name of anti-sense oligonucleotide therapy (AOT).  There have been decades of research from both European and American based companies and universities on SOT/AOT.  RGCC labs has improved this technology and renamed it SOT because the treatment is now based on the patient’s unique genetic molecules.  We know of no other laboratory in the world that is creating this unique process.  In the United States, we now cure Hepatitis C with this exact same FDA approved technology.  If we can turn off Hepatitis C with one dose of an anti-sense therapy then we can turn off the same replication cycles of Lyme Disease, Lyme co-infections, viruses and even cancer cells, thus making SOT a curative therapy.

Over the past two decades, AOT technology has emerged as a valid approach to selectively modulate gene expressions in various targets.  The recent acceleration of science and the ability to identify new molecular targets for cancer, Lyme and other viruses, has driven new advances in this technology.  The limited effectiveness of conventional treatment strategies has focused considerable interest on the technology and development of these new types of gene silencing therapies.

How does SOT work?

After a lab draw, we very quickly send the patient’s blood to RGCC labs in Greece.   RGCC will then identify the main genetic sequence (gene epitope) of your target genes and then the gene sequences are cross referenced to an international database of genetics to confirm they have the proper sequences.  RGCC created this unique fingerprinting technology, which ensures success of the treatment.  It creates a 98% specificity to our target genes, such as the Lyme spirochetes or viruses, and it does not interfere with any other human cells.  Once the replication genes are identified, the laboratory creates the anti-copy of the replication of the translocation genes (sense strand).  RGCC splices apart this sense strand and makes a complimentary copy of the DNA sequences that creates replication.  This in turn creates an anti-sense therapy.  When the genetic sequence of a particular gene is known to be a causative agent of particular disease, it is possible to synthesize a strand of nucleic acid (DNA, RNA or a chemical analogue) that will bind to the messenger RNA (mRNA) produced by that gene and effectively turning that gene “off.” This is called gene silencing therapy or apoptosis inducing therapy.

Once they create the complimentary copy of the replication sequences, they surround this copy with a synthetic mRNA so that it has the ability to penetrate within the cell wall of our target.  Once this mRNA sequence is created, it is replicated 500 million to 1 billion times producing a large number of your unique SOT molecules.  These molecules are delivered to our office where you receive your one dose IV treatment.

After infusion of the SOT molecules, the nucleotides are at work 24 hours a day, seven days a week for up to six months, constantly inhibiting the replication cycle of your target viruses or spirochetes.  This makes SOT a curative approach to our target focus which can be Lyme, cancer or any other virus that differs from the genetics of our original gene structure.

SOT can be given every 4-6 months (up to 3 times per year), as needed when Lyme/viral infection is indicated.

Lyme

Lyme Disease is a tick-borne illness caused by a spirochete. The Lyme spirochetes have a life cycle of 80 days, which is the longest life cycle of any bacteria in science. It also has one of the most complicated gene sequences that we study.  It is important to note that SOT treatment is not an immune treatment and it does not work through the immune activation system, therefore there is very minimal side effects.  SOT works simply by shutting down the gene replication sequences of our target, therefore eliminating the next life cycle.  Once the life cycle of the spirochete has been completed there are just simply no spirochetes left.

Prime Spot

If you choose to do Prime Spot testing through BioCentaur, the blood draw process is still the same and your specimen is still sent to RGCC in Greece.  Your blood will be forwarded to BioCentaur in the UK to be analyzed to identify the active viruses in order of which viruses are affecting the individual the most.   The SOT will then be created to specifically target the virus that is causing the most harm.

Viruses that the Prime Spot can identify:

  • Epstein Barr Virus (EBV-HHV4)
  • Human Herpes Simplex Virus 1 and 2 (HHV1, HHV2)
  • Varicella Zoster (Shingles-HHV3)
  • Cytomegalovirus (CMV-HHV5)
  • Human Immunodeficiency Virus (HIV)
  • Coxsackie Virus
  • Human Papilloma Virus (HPV16, HPV18)
  • Hepatitis B (HBV)
  • Hepatitis C (HCV)
  • Human T-cell Lymphotropic Virus (HTLV1)
  • Xenotropic Murine Leukemia Virus (XMVR)
  • Kaposi Sarcoma Virus (HHV8)

Lyme Infections that Prime Spot can identify:

  • Borrelia mayonii
  • Borrelia burgdorferi
  • Borrelia garinii

 

The following 11 Lyme species are available with SOT with positive labs from an approved lab:

  1. B. bissettii
  2. B. bavariensis Candidatus
  3. Borrelia tachyglossi
  4. B. valaisiana
  5. B. afzelii
  6. B. fimlamdemsis
  7. B. microti
  8. B. bigemina
  9. B. divergens
  10. B. duncani
  11. B. bovis

 

**Any virus not listed will take about 5-6 weeks for the lab to attempt to develop the correct SOT for that virus.  You will need a positive lab from an approved USA lab or the Prime Spot not older than 6 months for any virus or spirochete you are requesting SOT to be made for.  It is also recommended to have blood tested between SOT treatments to allow for more aggressive targeting as viruses and Lyme can mutate.

 

Resources:

Research Study:  http://globalresearchonline.net/journalcontents/volume9issue2/Article-007.pdf